United States Pharmacopeial Convention, Inc

U.S. Pharmacopeia XX, (USP XX-NF XV), The United States Pharmacopeial Convention Inc., Rockville, Md., 1980 National Formulary XIW, Amehcan Pharmaceutical Association, Washington, D.C., 1975. 

USAN and USP Dictionay of Drug Names, United States Pharmacopeial Convention, Inc., Rockville, Md., 1990. 

The United States Pharmacopeial Convention, Inc. (USP) in 2000 issued the USP criteria for levels of evidence for botanical articles [117]. While issued for botanicals, the criteria have application to all therapeutic agents. The USP criteria rank evidence from I to IV, with Level I being the strongest. Within Level I, the randomized controlled clinical trial is ranked highest, followed by meta-analysis and epidemiological studies. Level II consists of the same designs, but with methodological flaws. Level III includes inconclusive studies, and Level IV is anecdotal evidence. 

USP. US Pharmacopeia National Formulary. Rockville United States Pharmacopeial Convention Inc., 2004. 

The FDA, in consultation with the United States Pharmacopeial Convention, Inc., shall promulgate regulations identifying drug substances that may be used in compounding for which a monograph does not exist or which are not components of drug products approved by the FDA. 

USP 24 Testing Chapters (51) Antimicrobial Effectiveness Testing, (61) Microbial Limit Tests and (71) Sterility Tests, United States Pharmacopeial Convention, Inc., Rockville, MD, 2000. USP 24 Informational Chapters (1116) Microbiological Evaluation of Clean Rooms and other Controlled Environments, (1111) Microbiological Attributes of Pharmaceutical Articles, (1151) Pharmaceutical Dosage Forms, (1225) Validation of Compendial Methods, and (1231) Water for Pharmaceutical Purposes, United States Pharmacopeial Convention, Inc., Rockville, MD, 2000. 

---